KORU Medical Systems

KRMD · NASDAQ

$3.04+$0.02 (+0.66%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.02

Latest news

Press releaseOct 20, 4:05 PM ETBusiness Wire
KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026
NewsAug 5, 4:08 PM ET
KORU Medical Systems Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $12.045M Beat $11.609M Estimate
Press releaseAug 5, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
Press releaseJul 29, 4:05 PM ETBusiness Wire
KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
Press releaseJul 22, 5:00 PM ETBusiness Wire
Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm
Press releaseJul 15, 4:05 PM ETBusiness Wire
KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
Press releaseMay 18, 4:05 PM ETBusiness Wire
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces First Quarter 2026 Results
Press releaseApr 16, 8:00 AM ETBusiness Wire
KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
Press releaseMar 13, 8:00 AM ETBusiness Wire
KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
NewsMar 12, 4:08 PM ET
KORU Medical Systems Q4 Adj. EPS $0.01 Beats $(0.02) Estimate, Sales $10.895M Beat $10.821M Estimate
Press releaseMar 12, 4:08 PM ETBusiness Wire
KORU Medical Systems Announces CEO Transition
Press releaseMar 12, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
NewsMar 12, 7:11 AM ET
Earnings Scheduled For March 12, 2026
Press releaseFeb 26, 4:05 PM ETBusiness Wire
KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Press releaseJan 29, 4:05 PM ETBusiness Wire
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
Press releaseJan 12, 8:00 AM ETBusiness Wire
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
Press releaseJan 5, 7:00 AM ETBusiness Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseDec 30, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
Press releaseDec 16, 4:05 PM ETBusiness Wire
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
Press releaseNov 17, 4:05 PM ETBusiness Wire
KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025
Press releaseNov 13, 8:00 AM ETBusiness Wire
KORU Medical Systems to Participate in Upcoming Investor Conferences
NewsNov 13, 7:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseNov 12, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
Press releaseNov 4, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems
Press releaseOct 22, 4:05 PM ETBusiness Wire
KORU Medical Systems to Report Third Quarter 2025 Financial Results on November 12, 2025
Press releaseSep 18, 8:00 AM ETBusiness Wire
ForCast Orthopedics and KORU Medical Systems Announce Agreement for Novel Antibiotic Infusion Therapy
NewsAug 7, 1:09 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
Press releaseAug 6, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance
Press releaseAug 1, 4:55 PM ETBusiness Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 7, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance
NewsFeb 6, 4:19 PM ET
KORU Medical Signs Agreement For Next-Gen Subcutaneous Infusion System With Global Pharmaceutical Company; Co Collaborates With SCHOTT Pharma
Press releaseFeb 6, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
Press releaseJan 30, 4:05 PM ETBusiness Wire
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
NewsJan 17, 5:00 PM ET
Analyst Expectations For KORU Medical Systems's Future
Press releaseNov 13, 4:05 PM ETBusiness Wire
KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance
Press releaseAug 7, 4:05 PM ETBusiness Wire
KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026

KORU Medical Systems Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $12.045M Beat $11.609M Estimate

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance

KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference

Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm

KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026

KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress

Earnings Scheduled For May 6, 2026

KORU Medical Systems Announces First Quarter 2026 Results

KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility

KORU Medical Systems Q4 Adj. EPS $0.01 Beats $(0.02) Estimate, Sales $10.895M Beat $10.821M Estimate

KORU Medical Systems Announces CEO Transition

KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance

Earnings Scheduled For March 12, 2026

KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer

KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025

KORU Medical Systems to Participate in Upcoming Investor Conferences

12 Health Care Stocks Moving In Thursday's Pre-Market Session

KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance

Earnings Scheduled For November 12, 2025

KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems

KORU Medical Systems to Report Third Quarter 2025 Financial Results on November 12, 2025

ForCast Orthopedics and KORU Medical Systems Announce Agreement for Novel Antibiotic Infusion Therapy

12 Health Care Stocks Moving In Thursday's Intraday Session

KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

KORU Medical Signs Agreement For Next-Gen Subcutaneous Infusion System With Global Pharmaceutical Company; Co Collaborates With SCHOTT Pharma

KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System

KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology

Analyst Expectations For KORU Medical Systems's Future

KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance